亨廷顿舞蹈症治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Huntingtons Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月08日 | 出版商:

Global Market Insights Inc. | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球亨廷顿舞蹈症治疗市值为4.575亿美元，预计2024-2032年复合年增长率为20.8%。这种增长是由亨廷顿舞蹈症的日益流行和医学研究的重大进步所推动的。诊断工具的改进和意识的提高导致了更多病例的发现，从而推动了对有效治疗的需求。基因检测的进步现在可以实现更早、更准确的诊断，从而促进及时介入。关键药物（例如丁苯那嗪）的仿製药的出现，使得治疗变得更加经济实惠和容易获得。此外，政府、製药公司和私人投资者增加的资金和投资正在加速新疗法的发现和开发，进一步促进市场扩张。

整个亨廷顿舞蹈症治疗产业根据药物、类型、配销通路和地区进行分类。

市面上将药物分为丁苯那嗪、丁苯那嗪和其他药物。 2023年，丁苯那嗪占据主导地位，占据47.8%的市场。丁苯那嗪可有效治疗舞蹈症（亨丁顿舞蹈症的主要症状）、减少不自主运动并改善运动功能。它作为亨廷顿氏舞蹈症的特定治疗方法的早期监管批准和认可巩固了其市场地位。品牌和仿製药形式的可用性提供了具有成本效益的治疗选择，保持了其重要的市场份额。

市场细分为品牌和通用类别。 2023 年，在既定功效和强大品牌认知度的推动下，品牌细分市场销售额达 2.58 亿美元。品牌药物受益于全面的监管批准和临床指南的频繁认可，巩固了其作为各种病症标准治疗的地位。广泛的营销活动和持续的研发投资进一步增强了品牌治疗的吸引力，确保它们始终处于医疗实践的前沿。

2023年，北美亨廷顿舞蹈症治疗市值为1.839亿美元，预计复合年增长率为20.7%。北美亨廷顿舞蹈症的盛行率很高，人们的认识和早期诊断能力也有所提高。改进的诊断工具和宣传活动导致了更高的诊断率和对有效治疗的更大需求。 2023 年，美国亨廷顿舞蹈症治疗市场价值为 1.677 亿美元，预计到 2032 年将达到 8.944 亿美元。

产业生态系统分析
产业影响力
- 成长动力
  - 亨丁顿舞蹈症的盛行率不断增加
  - 增加与亨丁顿舞蹈症相关的研发活动
  - 人们对这种疾病的认识不断增强
- 产业陷阱与挑战
  - 有效治疗的可用性有限
  - 严格的监管要求
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药品分类，2021 - 2032 年

主要趋势
丁苯那嗪
丁苯那嗪
其他药品

第 6 章：市场估计与预测：按类型，2021 - 2032

主要趋势
品牌化
通用的

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Bausch Health Companies Inc.
CHEPLAPHARM Arzneimittel GmbH
Dr. Reddy's Laboratories Ltd.
H. Lundbeck A/S
Hikma Pharmaceuticals PLC
Lupin Limited
Neurocrine Biosciences, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Upsher-Smith Laboratories, LLC.

简介目录

Product Code: 10732

The Global Huntington's Disease Treatments Market was valued at USD 457.5 million in 2023, with a projected CAGR of 20.8% over 2024-2032. This growth is fueled by the increasing prevalence of Huntington's disease and significant advancements in medical research. Improved diagnostic tools and greater awareness have led to the identification of more cases, driving the demand for effective treatments. Advances in genetic testing now enable earlier and more accurate diagnoses, facilitating timely interventions. The availability of generic versions of key medications, such as tetrabenazine, has made treatments more affordable and accessible. Additionally, increased funding and investment from governments, pharmaceutical companies, and private investors, are accelerating the discovery and development of new therapies, further contributing to market expansion.

The overall huntingtons disease treatment industry is classified based on the drugs, type, distribution channel, and region.

The market categorizes drugs into tetrabenazine, deutetrabenazine, and other medications. In 2023, tetrabenazine dominated with a 47.8% market share. Tetrabenazine is effective for managing chorea, a major symptom of Huntington's disease, reducing involuntary movements, and improving motor function. Its early regulatory approval and recognition as a specific treatment for Huntington's disease solidifies its market position. Availability in both branded and generic forms provides cost-effective treatment options, maintaining its significant market share.

The market segments treatments into branded and generic categories. In 2023, the branded segment accounted for USD 258 million, driven by established efficacy and strong brand recognition. Branded medications benefit from comprehensive regulatory approval and frequent endorsements in clinical guidelines, reinforcing their position as standard treatments for various conditions. Extensive marketing campaigns and continued investment in research and development further strengthen the appeal of branded treatments, ensuring they remain at the forefront of medical practice.

In 2023, the North American market for Huntington's disease treatments was valued at USD 183.9 million, with a projected CAGR of 20.7%. North America has a high prevalence of Huntington's disease, coupled with increased awareness and early diagnostic capabilities. Improved diagnostic tools and awareness campaigns have led to higher diagnosis rates and greater demand for effective treatments. In 2023, the U.S. market for Huntington's disease treatments was valued at USD 167.7 million, projected to reach USD 894.4 million by 2032. The U.S. is a hub for pharmaceutical R&D, with significant investments in developing new therapies for Huntington's disease, supporting growth in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of Huntington's disease
  - 3.2.1.2 Increased research and development activities related to Huntington's disease
  - 3.2.1.3 Growing awareness related to the disease
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Limited availability of effective treatment
  - 3.2.2.2 Stringent regulatory requirement
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drugs, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Tetrabenazine
5.3 Deutetrabenazine
5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Branded
6.3 Generic

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa